GPC2 CAR-T cell therapy(Childrens Hospital of Philadelphia/Tmunity Therapeutics)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameGPC2 CAR-T cell therapy(Childrens Hospital of Philadelphia/Tmunity Therapeutics)
Drug Alias NameTmGPC2-01-CAR-T
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityGlypican-2 inhibitors +[4] 
TargetsGlypican-2
Therapy Area/IndicationsUrinary Bladder NeoplasmsSmall Cell Lung CarcinomaRetinoblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesChildrens Hospital of Philadelphia
China Registration ClassN/A

Develop Information

Active CompaniesChildrens Hospital of Philadelphia
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsSmall Cell Lung CarcinomaRetinoblastoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A